05.06.2013 - After having raised €19m, Belgian reg-med specialist Cardio3 BioSciences has hunger for more. The company announced to go public.
Only two weeks after a capital increase, the company said it will launch an IPO at NYSE Euronext Brussels and NYSE Euronext Paris to raise new funds. Cardio3 BioSciences' lead product C-CureR (C3BS-CQR-1) has been moved to Phase III development following promising results.
Through a process called cardiopoiesis, the company can reprogramme bone marrow cells to become heart precursor cells. Cardio3 BioSciences wants to use them to repair heart failure secondary to ischemic heart disease. The IP was licenced from the US Mayo Clinic (Rochester, Minnesota).
Heart failure is one of the world's greatest unmet medical needs. At 40 years old, a person has a one in five risk of developing heart failure and, once the disorder is apparent, a one in three chance of dying within a year of diagnosis. US$32bn annually is spent on heart failure patients in the US alone.
C3BS-CQR-1 is currently being tested in Europe in the CHART-1 trial, the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure. Phase II results pointed to an increase of 25% of the Left Ventricular Ejection Fraction (LVEF) which was statistically significant (p<0.0001), as was the increase in exercise capacity measured by the 6 minutes Walking Distance test (+77m change at 6 months versus baseline in comparison to the control group (p<0.01). Cardio3 BioSciences intends to start a trial in the US (the CHART-2 trial if the FDA authorizes its start. The CHART programme is designed as two pivotal studies to obtain marketing authorisation in Europe and in the USA respectively, either alone, or in combination with other clinical trials.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more